Thalamic dysfunction in schizophrenia: Neurochemical, neuropathological, and in vivo imaging abnormalities

Schizophrenia Research

Volumn 69, Issue 2-3, 2004, Pages 237-253

  Clinton, Sarah M ^a   Meador Woodruff, James H ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Dorsomedial nucleus; GABA; Glutamate; NMDA receptor; PSD95; Thalamus

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR; AMPAKINE DERIVATIVE; AMPHETAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; GLUTAMIC ACID; HALOPERIDOL; IONOTROPIC RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; UNCLASSIFIED DRUG;

AUTOPSY; AUTORADIOGRAPHY; BRAIN CORTEX; BRAIN DYSFUNCTION; BRAIN METABOLISM; BRAIN NERVE CELL; BRAIN SIZE; CHROMATOGRAPHY; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; DISEASE EXACERBATION; DOPAMINERGIC TRANSMISSION; HUMAN; IN SITU HYBRIDIZATION; INFORMATION PROCESSING; NEUROCHEMISTRY; NEUROPATHOLOGY; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SENSORY STIMULATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMATOSENSORY SYSTEM; STEREOLOGY; TEMPORAL LOBE; THALAMOCORTICAL TRACT; VISUAL INFORMATION;

EID: 2642514620     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2003.09.017     Document Type: Article

References (151)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E. Jr., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry. 52:1995;258-266
2. Alfredsson G., Wiesel F.A. Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology. 99:1989;322-327
3. Andreasen N.C., Ehrhardt J.C., Swayze V.W. II, Alliger R.J., Yuh W.T., Cohen G., Ziebell S. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch. Gen. Psychiatry. 47:1990;35-44
4. Andreasen N.C., Rezai K., Alliger R., Swayze V.W. II, Flaum M., Kirchner P., Cohen G., O'Leary D.S. Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. Arch. Gen. Psychiatry. 49:1992;943-958
5. Andreasen N.C., Arndt S., Swayze V. II, Cizadlo T., Flaum M., O'Leary D., Ehrhardt J.C., Yuh W.T. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science. 266:1994;294-298
6. Andreasen N.C., O'Leary D.S., Cizadlo T., Arndt S., Rezai K., Ponto L.L., Watkins G.L., Hichwa R.D. Schizophrenia and cognitive dysmetria: a positron-emission tomography study of dysfunctional prefrontal-thalamic- cerebellar circuitry. Proc. Natl. Acad. Sci. U. S. A. 93:1996;9985-9990
7. Andreasen N.C., O'Leary D.S., Flaum M., Nopoulos P., Watkins G.L., Boles Ponto L.L., Hichwa R.D. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 349:1997;1730-1734
8. Andreasen N.C., Paradiso S., O'Leary D.S. "Cognitive dysmetria" as an integrative theory of schizophrenia: a dysfunction in cortical-subcortical-cerebellar circuitry? Schizophr. Bull. 24:1998;203-218
9. Arciniegas D., Rojas D.C., Teale P., Sheeder J., Sandberg E., Reite M. The thalamus and the schizophrenia phenotype: failure to replicate reduced volume. Biol. Psychiatry. 45:1999;1329-1335
10. Auer D.P., Wilke M., Grabner A., Heidenreich J.O., Bronisch T., Wetter T.C. Reduced NAA in the thalamus and altered membrane and glial metabolism in schizophrenic patients detected by 1H-MRS and tissue segmentation. Schizophr. Res. 52:2001;87-99
11. Bagary M.S., Foong J., Maier M., duBoulay G., Barker G.J., Miller D.H., Ron M.A. A magnetization transfer analysis of the thalamus in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 14:2002;443-448
12. Bartlett E.J., Wolkin A., Brodie J.D., Laska E.M., Wolf A.P., Sanfilipo M. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res. 40:1991;115-124
13. Bellocchio E.E., Hu H., Pohorille A., Chan J., Pickel V.M., Edwards R.H. The localization of the brain-specific inorganic phosphate transporter suggests a specific presynaptic role in glutamatergic transmission. J. Neurosci. 18:1998;8648-8659
14. Bellocchio E.E., Reimer R.J., Fremeau R.T. Jr., Edwards R.H. Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science. 289:2000;957-960
15. Benes F.M., Vincent S.L., Alsterberg G., Bird E.D., SanGiovanni J.P. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J. Neurosci. 12:1992;924-929
16. Benes F.M., Khan Y., Vincent S.L., Wickramasinghe R. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse. 22:1996;338-349
17. Benes F.M., Vincent S.L., Marie A., Khan Y. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience. 75:1996;1021-1031
18. Benes F.M., Wickramasinghe R., Vincent S.L., Khan Y., Todtenkopf M. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res. 755:1997;121-129
19. Benes F.M., Kwok E.W., Vincent S.L., Todtenkopf M.S. A reduction of nonpyramidal cells in sector CA2 of schizophrenics and manic depressives. Biol. Psychiatry. 44:1998;88-97
20. Bertolino A., Nawroz S., Mattay V.S., Barnett A.S., Duyn J.H., Moonen C.T., Frank J.A., Tedeschi G., Weinberger D.R. Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. Am. J. Psychiatry. 153:1996;1554-1563
21. Bjerkenstedt L., Edman G., Hagenfeldt L., Sedvall G., Wiesel F.A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br. J. Psychiatry. 147:1985;276-282
22. Breier A., Su T.P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2569-2574
23. Brenman J., Topinka J., Cooper E., McGee A., Rosen J., Milroy T., Ralston H., Bredt D. Localization of postsynaptic density-93 to dendritic microtubules and interaction with microtubule-associated protein 1A. J. Neurosci. 18:1998;8805-8813
24. Bridle N., Pantelis C., Wood S.J., Coppola R., Velakoulis D., McStephen M., Tierney P., Le T.L., Torrey E.F., Weinberger D. Thalamic and caudate volumes in monozygotic twins discordant for schizophrenia. Aust. N. Z. J. Psychiatry. 36:2002;347-354
25. Brown R.M., Crane A.M., Goldman P.S. Regional distribution of monoamines in the cerebral cortex and subcortical structures of the rhesus monkey: concentrations and in vivo synthesis rates. Brain Res. 168:1979;133-150
26. Buchsbaum M.S. The frontal lobes, basal ganglia, and temporal lobes as sites for schizophrenia. Schizophr. Bull. 16:1990;379-389
27. Buchsbaum M.S., Hazlett E.A. Functional brain imaging and aging in schizophrenia. Schizophr. Res. 27:1997;129-141
28. Buchsbaum M.S., Hazlett E.A. Positron emission tomography studies of abnormal glucose metabolism in schizophrenia. Schizophr. Bull. 24:1998;343-364
29. Buchsbaum M.S., Wu J.C., DeLisi L.E., Holcomb H.H., Hazlett E., Cooper-Langston K., Kessler R. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biol. Psychiatry. 22:1987;479-494
30. Buchsbaum M.S., Potkin S.G., Siegel B.V. Jr., Lohr J., Katz M., Gottschalk L.A., Gulasekaram B., Marshall J.F., Lottenberg S., Teng C.Y., et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch. Gen. Psychiatry. 49:1992;966-974
31. Buchsbaum M.S., Someya T., Teng C.Y., Abel L., Chin S., Najafi A., Haier R.J., Wu J., Bunney W.E. Jr. PET and MRI of the thalamus in never-medicated patients with schizophrenia. Am. J. Psychiatry. 153:1996;191-199
32. Byne W., Buchsbaum M.S., Kemether E., Hazlett E.A., Shinwari A., Mitropoulou V., Siever L.J. Magnetic resonance imaging of the thalamic mediodorsal nucleus and pulvinar in schizophrenia and schizotypal personality disorder. Arch. Gen. Psychiatry. 58:2001;133-140
33. Byne W., Buchsbaum M.S., Mattiace L.A., Hazlett E.A., Kemether E., Elhakem S.L., Purohit D.P., Haroutunian V., Jones L. Postmortem assessment of thalamic nuclear volumes in subjects with schizophrenia. Am. J. Psychiatry. 159:2002;59-65
34. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. Am. J. Psychiatry. 151:1994;1430-1436
35. Clinton S.M., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Altered expression of NMDA receptor-associated post-synaptic density proteins in the thalamus in schizophrenia. Am. J. Psychiatry. 160:2003;1100-1109
36. Cooper J.R., Bloom F.E., Roth R.H. The Biochemical Basis of Neuropharmacology. 6th ed. 1991;Oxford Univ. Press, New York
37. Corey-Bloom J., Jernigan T., Archibald S., Harris M.J., Jeste D.V. Quantitative magnetic resonance imaging of the brain in late-life schizophrenia. Am. J. Psychiatry. 152:1995;447-449
38. Cross A.J., Crow T.J., Owen F. Gamma-aminobutyric acid in the brain in schizophrenia. Lancet. 1:1979;560-561
39. Cullen T.J., Walker M.A., Parkinson N., Craven R., Crow T.J., Esiri M.M., Harrison P.J. A postmortem study of the mediodorsal nucleus of the thalamus in schizophrenia. Schizophr. Res. 60:2003;157-166
40. Damadzic R., Bigelow L.B., Krimer L.S., Goldenson D.A., Saunders R.C., Kleinman J.E., Herman M.M. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res. Bull. 55:2001;611-618
41. Danos P., Baumann B., Bernstein H.G., Franz M., Stauch R., Northoff G., Krell D., Falkai P., Bogerts B. Schizophrenia and anteroventral thalamic nucleus: selective decrease of parvalbumin-immunoreactive thalamocortical projection neurons. Psychiatry Res. 82:1998;1-10
42. Danos P., Baumann B., Bernstein H.G., Stauch R., Krell D., Falkai P., Bogerts B. The ventral lateral posterior nucleus of the thalamus in schizophrenia: a post-mortem study. Psychiatry Res. 114:2002;1-9
43. Danos P., Baumann B., Kramer A., Bernstein H.G., Stauch R., Krell D., Falkai P., Bogerts B. Volumes of association thalamic nuclei in schizophrenia: a postmortem study. Schizophr. Res. 60:2003;141-155
44. Dasari M., Friedman L., Jesberger J., Stuve T.A., Findling R.L., Swales T.P., Schulz S.C. A magnetic resonance imaging study of thalamic area in adolescent patients with either schizophrenia or bipolar disorder as compared to healthy controls. Psychiatry Res. 91:1999;155-162
45. Davis K.L., Stewart D.G., Friedman J.I., Buchsbaum M., Harvey P.D., Hof P.R., Buxbaum J., Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch. Gen. Psychiatry. 60:2003;443-456
46. Deicken R.F., Johnson C., Eliaz Y., Schuff N. Reduced concentrations of thalamic N-acetylaspartate in male patients with schizophrenia. Am. J. Psychiatry. 157:2000;644-647
47. Deicken R.F., Eliaz Y., Chosiad L., Feiwell R., Rogers L. Magnetic resonance imaging of the thalamus in male patients with schizophrenia. Schizophr. Res. 58:2002;135-144
48. Delamillieure P., Constans J., Fernandez J., Brazo P., Dollfus S. Proton magnetic resonance spectroscopy (1H-MRS) of the thalamus in schizophrenia. Eur. Psychiatr. 15:2000;489-491
49. Delamillieure P., Constans J., Fernandez J., Brazo P., Dollfus S. Proton magnetic resonance spectroscopy (1HMRS) in schizophrenia: investigation of the right and left hippocampus, thalamus, and prefrontal cortex. Schizophr. Bull. 28:2002;329-339
50. DeLisi L.E., Holcomb H.H., Cohen R.M., Pickar D., Carpenter W., Morihisa J.M., King A.C., Kessler R., Buchsbaum M.S. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J. Cereb. Blood Flow Metab. 5:1985;201-206
51. Dracheva S., Marras S.A., Elhakem S.L., Kramer F.R., Davis K.L., Haroutunian V. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am. J. Psychiatry. 158:2001;1400-1410
52. Ende G., Braus D.F., Walter S., Henn F.A. Lower concentration of thalamic n-acetylaspartate in patients with schizophrenia: a replication study. Am. J. Psychiatry. 158:2001;1314-1316
53. Ettinger U., Chitnis X.A., Kumari V., Fannon D.G., Sumich A.L., O'Ceallaigh S., Doku V.C., Sharma T. Magnetic resonance imaging of the thalamus in first-episode psychosis. Am. J. Psychiatry. 158:2001;116-118
54. Farde L., Wiesel F.A., Stone-Elander S., Halldin C., Nordstrom A.L., Hall H., Sedvall G. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch. Gen. Psychiatry. 47:1990;213-219
55. Flaum M., Swayze V.W. II, O'Leary D.S., Yuh W.T., Ehrhardt J.C., Arndt S.V., Andreasen N.C. Effects of diagnosis, laterality, and gender on brain morphology in schizophrenia. Am. J. Psychiatry. 152:1995;704-714
56. Gao X.M., Sakai K., Roberts R.C., Conley R.R., Dean B., Tamminga C.A. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am. J. Psychiatry. 157:2000;1141-1149
57. Gattaz W.F., Gattaz D., Beckmann H. Glutamate in schizophrenics and healthy controls. Arch. Psychiatr. Nervenkr. 231:1982;221-225
58. Gattaz W.F., Gasser T., Beckmann H. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls. Biol. Psychiatry. 20:1985;360-366
59. Gegelashvili G., Civenni G., Racagni G., Danbolt N.C., Schousboe I., Schousboe A. Glutamate receptor agonists up-regulate glutamate transporter GLAST in astrocytes. NeuroReport. 8:1996;261-265
60. Gilbert A.R., Rosenberg D.R., Harenski K., Spencer S., Sweeney J.A., Keshavan M.S. Thalamic volumes in patients with first-episode schizophrenia. Am. J. Psychiatry. 158:2001;618-624
61. Goff D.C., Coyle J.T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158:2001;1367-1377
62. Goff D., Tsai G., Manoach D., Coyle J. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am. J. Psychiatry. 152:1995;1213-1215
63. Goff D.C., Tsai G., Manoach D.S., Flood J., Darby D.G., Coyle J.T. D-cycloserine added to clozapine for patients with schizophrenia. Am. J. Psychiatry. 153:1996;1628-1630
64. Goff D., Berman I., Posever T., Herz L., Leahy L., Lynch G. A preliminary dose escalation trial of CX516 (Ampakine) added to clozapine in schizophrenia. Schizophr. Res. 36:1999;280
65. Goldman-Rakic P.S., Brown R.M. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience. 6:1981;177-187
66. Gur R.E., Maany V., Mozley P.D., Swanson C., Bilker W., Gur R.C. Subcortical MRI volumes in neuroleptic-naive and treated patients with schizophrenia. Am. J. Psychiatry. 155:1998;1711-1717
67. Gurevich E.V., Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons. Neuropsychopharmacology. 20:1999;60-80
68. Hall H., Farde L., Halldin C., Hurd Y.L., Pauli S., Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse. 23:1996;115-123
69. Hanada S., Mita T., Nishino N., Tanaka C. [3H]muscimol binding sites increased in autopsied brains of chronic schizophrenics. Life Sci. 40:1987;259-266
70. Hazlett E.A., Buchsbaum M.S., Byne W., Wei T.C., Spiegel-Cohen J., Geneve C., Kinderlehrer R., Haznedar M.M., Shihabuddin L., Siever L.J. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am. J. Psychiatry. 156:1999;1190-1199
71. Heckers S., Konradi C. Hippocampal neurons in schizophrenia. J. Neural Transm. 109:2002;891-905
72. Heckers S., Rauch S.L., Goff D., Savage C.R., Schacter D.L., Fischman A.J., Alpert N.M. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia. Nat. Neurosci. 1:1998;318-323
73. Heckers S., Stone D., Walsh J., Shick J., Koul P., Benes F.M. Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch. Gen. Psychiatry. 59:2002;521-529
74. Heimberg C., Komoroski R.A., Lawson W.B., Cardwell D., Karson C.N. Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect. Psychiatry Res. 83:1998;105-115
75. Hof P.R., Haroutunian V., Copland C., Davis K.L., Buxbaum J.D. Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochem. Res. 27:2002;1193-1200
76. Holcomb H., Cascella N., Thaker G., Medoff D., Dannals R., Tamminga C. Funcitonal sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry. 153:1996;41-49
77. Horio Y., Hibino H., Inanobe A., Yamada M., Ishii M., Tada Y., Satoh E., Hata Y., Takai Y., Kurachi Y. Clustering and enhanced activity of an inwardly rectifying potassium channel, Kir4.1, by an anchoring protein, PSD-95/SAP90. J. Biol. Chem. 272:1997;12885-12888
78. Ibrahim H., Hogg A., Healy D., Haroutunian V., Davis K., Meador-Woodruff J. Ionotropic glutamate Receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am. J. Psychiatry. 157:2000;1811-1823
79. Javitt D., Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry. 148:1991;1301-1308
80. Javitt D., Zylberman I., Zukin S., Heresco-Levy U., Lindenmayer J. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry. 151:1994;1234-1336
81. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225
82. Jernigan T.L., Zisook S., Heaton R.K., Moranville J.T., Hesselink J.R., Braff D.L. Magnetic resonance imaging abnormalities in lenticular nuclei and cerebral cortex in schizophrenia. Arch. Gen. Psychiatry. 48:1991;881-890
83. Jones E.G. Cortical development and thalamic pathology in schizophrenia. Schizophr. Bull. 23:1997;483-501
84. Jones E.G. The thalamus of primates. Bloom F.E., Bjorklund A., Hokfelt T. The Primate Nervous System, Part II. 1998;1-246 Elsevier, New York
85. Kanai Y., Smith C.P., Hediger M.A. A new family of neurotransmitter transporters: the high-affinity glutamate transporters. FASEB J. 7:1993;1450-1459
86. Kegeles L.S., Humaran T.J., Mann J.J. In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy. Biol. Psychiatry. 44:1998;382-398
87. Kessler R.M., Whetsell W.O., Ansari M.S., Votaw J.R., de Paulis T., Clanton J.A., Schmidt D.E., Mason N.S., Manning R.G. Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride. Brain Res. 609:1993;237-243
88. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382
89. Kiryu S., Yao G., Morita N., Kato H., Kiyama H. Nerve injury enhances rat neuronal glutamate transporter expression: identification by differential display PCR. J. Neurosci. 15:1995;7872-7878
90. Kling A.S., Metter E.J., Riege W.H., Kuhl D.E. Comparison of PET measurement of local brain glucose metabolism and CAT measurement of brain atrophy in chronic schizophrenia and depression. Am. J. Psychiatry. 143:1986;175-180
91. Konick L.C., Friedman L. Meta-analysis of thalamic size in schizophrenia. Biol. Psychiatry. 49:2001;28-38
92. Korpi E.R., Kaufmann C.A., Marnela K.M., Weinberger D.R. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res. 20:1987;337-345
93. Lahti A., Holcomb H., Medoff D., Tamminga C. Ketamine activates psychosis and alters limbic blood flow in schizophrenia. NeuroReport. 6:1995;869-872
94. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 93:1996;9235-9240
95. Laruelle M., Abi-Dargham A., Gil R., Kegeles L., Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry. 46:1999;56-72
96. Lavin A., Grace A. Response of the ventral pallidal/mediodorsal thalamic system to antipsychotic drug administration: involvement of the prefrontal cortex. Neuropsychopharmacology. 18:1998;352-363
97. Lavin A., Grace A.A. Dopamine modulates the responsivity of mediodorsal thalamic cells recorded in vitro. J. Neurosci. 18:1998;10566-10578
98. Lewis D.A., Lieberman J.A. Catching up on schizophrenia: natural history and neurobiology. Neuron. 28:2000;325-334
99. Lewis D.A., Cruz D.A., Melchitzky D.S., Pierri J.N. Lamina-specific deficits in parvalbumin-immunoreactive varicosities in the prefrontal cortex of subjects with schizophrenia: evidence for fewer projections from the thalamus. Am. J. Psychiatry. 158:2001;1411-1422
100. Macciardi F., Lucca A., Catalano M., Marino C., Zanardi R., Smeraldi E. Amino acid patterns in schizophrenia: some new findings. Psychiatry Res. 32:1990;63-70
101. Mansour A., Meador-Woodruff J.H., Lopez J.F., Watson S.J. Biochemical anatomy: insights into the cell biology and pharmacology of the dopamine and serotonin systems in the brain. Schatzberg A.F., Nemeroff C.B. Textbook of Pharmacology. 2nd ed. 1998;55-73 American Psychiatric Press, Washington, DC
102. Meador-Woodruff J.H. Novel D2-like dopamine receptors in schizophrenic brain. Gattaz W.F., Hafner H. Search for the Causes of Schizophrenia. 1999;251-260 Springer, New York
103. Meador-Woodruff J.H., Healy D.J. Glutamate receptor expression in schizophrenic brain. Brain Res. Brains Res. Rev. 31:2000;288-294
104. Melchitzky D.S., Lewis D.A. Dopamine transporter-immunoreactive axons in the mediodorsal thalamic nucleus of the macaque monkey. Neuroscience. 103:2001;1033-1042
105. Moore R.Y., Bloom F.E. Central catecholamine neuron systems: anatomy and physiology of the dopamine systems. Annu. Rev. Neurosci. 1:1978;129-169
106. Munoz A., Huntsman M.M., Jones E.G. GABA(B) receptor gene expression in monkey thalamus. J. Comp. Neurol. 394:1998;118-126
107. Ohnuma T., Kato H., Arai H., Faull R., McKenna P., Emson P. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. NeuroReport. 11:2000;3133-3137
108. Oke A.F., Adams R.N. Elevated thalamic dopamine: possible link to sensory dysfunctions in schizophrenia. Schizophr. Bull. 13:1987;589-604
109. Oke A., Solnick J., Adams R.N. Catecholamine distribution patterns in rat thalamus. Brain Res. 269:1983;180-183
110. Oke A.F., Adams R.N., Winblad B., von Knorring L. Elevated dopamine/norepinephrine ratios in thalami of schizophrenic brains. Biol. Psychiatry. 24:1988;79-82
111. Oke A.F., Putz C., Adams R.N., Bird E.D. Neuroleptic treatment is an unlikely cause of elevated dopamine in thalamus of schizophrenic subjects. Psychiatry Res. 45:1992;203-208
112. Olney J.W., Newcomer J.W., Farber N.B. NMDA receptor hypofunction model of schizophrenia. J. Psychiatr. Res. 33:1999;523-533
113. Omori M., Pearce J., Komoroski R.A., Griffin W.S., Mrak R.E., Husain M.M., Karson C.N. In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia. Biol. Psychiatry. 42:1997;359-366
114. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch. Gen. Psychiatry. 47:1990;1023-1028
115. Pakkenberg B. The volume of the mediodorsal thalamic nucleus in treated and untreated schizophrenics. Schizophr. Res. 7:1992;95-100
116. Pakkenberg B. Leucotomized schizophrenics lose neurons in the mediodorsal thalamic nucleus. Neuropathol. Appl. Neurobiol. 19:1993;373-380
117. Perry T.L. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction. Neurosci. Lett. 28:1982;81-85
118. Perry T.L., Kish S.J., Buchanan J., Hansen S. Gamma-aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet. 1:1979;237-239
119. Popken G.J., Bunney W.E. Jr., Potkin S.G., Jones E.G. Subnucleus-specific loss of neurons in medial thalamus of schizophrenics. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9276-9280
120. Popken G.J., Leggio M.G., Bunney W.E., Jones E.G. Expression of mRNAs related to the GABAergic and glutamatergic neurotransmitter systems in the human thalamus: normal and schizophrenic. Thalamus Relat. Syst. 1:2002;349-369
121. Portas C., Goldstein J., Shenton M., Hokama H., Wible C., Fischer I., Kikinis R., Donnino R., Jolesz F., McCarley R. Volumetric evaluation of the thalamus in schizophrenic male patients using magnetic resonance imaging. Biol. Psychiatry. 43:1998;649-659
122. Rajkowska G., Selemon L.D., Goldman-Rakic P.S. Neuronal and glial somal size in the prefrontal cortex: a postmortem morphometric study of schizophrenia and Huntington disease. Arch. Gen. Psychiatry. 55:1998;215-224
123. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Meltzer H., Overholser J., Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr. Res. 57:2002;127-138
124. Resnick S.M., Gur R.E., Alavi A., Gur R.C., Reivich M. Positron emission tomography and subcortical glucose metabolism in schizophrenia. Psychiatry Res. 24:1988;1-11
125. Richardson-Burns S., Haroutunian V., Davis K., Watson S., Meador-Woodruff J. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol. Psychiatry. 47:2000;22-28
126. Rothstein J.D., Martin L., Levey A.I., Dykes-Hoberg M., Jin L., Wu D., Nash N., Kuncl R.W. Localization of neuronal and glial glutamate transporters. Neuron. 13:1994;713-725
127. Rutter A., Stephenson F. Coexpression of postsynaptic density-95 protein with NMDA receptors results in enhanced receptor expression together with a decreased sensitivity to L-glutamate. J. Neurochem. 75:2000;2501-2510
128. Salt T.E., Eaton S.A. Functions of ionotropic and metabotropic glutamate receptors in sensory transmission in the mammalian thalamus. Prog. Neurobiol. 48:1996;55-72
129. Scheibel A.B. The thalamus and neuropsychiatric illness. J. Neuropsychiatry Clin. Neurosci. 9:1997;342-353
130. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch. Gen. Psychiatry. 52:1995;805-818
131. Selemon L.D., Rajkowska G., Goldman-Rakic P.S. Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: application of a three-dimensional, stereologic counting method. J. Comp. Neurol. 392:1998;402-412
132. Sheng M. The postsynaptic NMDA-receptor-PSD-95 signaling complex in excitatory synapses of the brain. J. Cell. Sci. 114:2001;1251
133. Sheng M.H.-T. The postsynaptic specialization. Cowan W.M., Sudhof T.C., Stevens C.F. Synapses. 2001;315-355 Johns Hopkins Univ. Press, Baltimore
134. Sheng M., Pak D. Ligand-gated ion channel interactions with cytoskeletal and signaling proteins. Annu. Rev. Physiol. 62:2000;755-778
135. Siegel B.V. Jr., Buchsbaum M.S., Bunney W.E. Jr., Gottschalk L.A., Haier R.J., Lohr J.B., Lottenberg S., Najafi A., Nuechterlein K.H., Potkin S.G., et al. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am. J. Psychiatry. 150:1993;1325-1336
136. Silbersweig D.A., Stern E., Frith C., Cahill C., Holmes A., Grootoonk S., Seaward J., McKenna P., Chua S.E., Schnorr L., et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature. 378:1995;176-179
137. Simpson M.D., Slater P., Deakin J.F., Royston M.C., Skan W.J. Reduced GABA uptake sites in the temporal lobe in schizophrenia. Neurosci. Lett. 107:1989;211-215
138. Smith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am. J. Psychiatry. 158:2001;1393-1399
139. Smith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Vesicular glutamate transporter transcript expression in the thalamus in schizophrenia. NeuroReport. 12:2001;2885-2887
140. Staal W.G., Hulshoff Pol H.E., Schnack H., van der Schot A.C., Kahn R.S. Partial volume decrease of the thalamus in relatives of patients with schizophrenia. Am. J. Psychiatry. 155:1998;1784-1786
141. Steriade M., Jones E.G., McCormick D.A. Thalamus: Organization and Function. 1997;Elsevier, Amsterdam
142. Suzuki M., Hurd Y.L., Sokoloff P., Schwartz J.C., Sedvall G. D3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 779:1998;58-74
143. Szechtman H., Nahmias C., Garnett E.S., Firnau G., Brown G.M., Kaplan R.D., Cleghorn J.M. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch. Gen. Psychiatry. 45:1988;523-532
144. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs L.D., Chase T.N., Carpenter W.T. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry. 49:1992;522-530
145. Tsai G., van Kammen D.P., Chen S., Kelley M.E., Grier A., Coyle J.T. Glutamatergic neurotransmission involves structural and clinical deficits of schizophrenia. Biol. Psychiatry. 44:1998;667-674
146. Vita A., Bressi S., Perani D., Invernizzi G., Giobbio G.M., Dieci M., Garbarini M., Del Sole A., Fazio F. High-resolution SPECT study of regional cerebral blood flow in drug-free and drug-naive schizophrenic patients. Am. J. Psychiatry. 152:1995;876-882
147. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., Lewis D.A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry. 57:2000;237-245
148. Wiesel F.A., Wik G., Sjogren I., Blomqvist G., Greitz T., Stone-Elander S. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates. Acta Psychiatr. Scand. 76:1987;628-641
149. Wik G., Wiesel F.A., Sjogren I., Blomqvist G., Greitz T., Stone-Elander S. Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacology (Berl). 97:1989;309-318
150. Wong D.F., Wagner H.N. Jr., Tune L.E., Dannals R.F., Pearlson G.D., Links J.M., Tamminga C.A., Broussolle E.P., Ravert H.T., Wilson A.A., et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 234:1986;1558-1563
151. Young K., Manaye K., Liang C., Hicks P., German D. Reduced number of mediodorsal and anterior thalamic neurons in schizophrenia. Biol. Psychiatry. 47:2000;944-953